May 26, 2020
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
May 11, 2020
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
Mar 23, 2020
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
Mar 04, 2020
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results
Nov 25, 2019
New Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
Nov 05, 2019
Cumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results
Oct 15, 2019
New Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia
Jul 31, 2019
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
May 07, 2019
Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
Feb 26, 2019
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Jan 07, 2019
Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
Nov 12, 2018
Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe
Nov 09, 2018
Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI(TM) (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease
Nov 06, 2018
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
Nov 06, 2018
Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
Oct 30, 2018
Theravance Biopharma to Report Third Quarter 2018 Financial Results on November 6
Oct 11, 2018
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Oct 10, 2018
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018
Oct 08, 2018
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Oct 08, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018